For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Novartis to Share Ex-Employee Hearing Info, Says “Gravely Concerned” about Media Reports
July 18, 2013
- Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
- BIKEN, JPRI to Merge in April
July 18, 2013
- MTPC to Strengthen Vaccine Development through Merger with Canadian Biotech Company Medicago
July 18, 2013
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- GSK Withdraws COPD Indication from NDA for ICS/LABA Combination Drug in Japan
July 17, 2013
- Astellas Launches Anticancer Agent Xtandi in UK
July 16, 2013
- Hisamitsu Initiates Domestic PII Study of Long-Acting Transdermal Allergic Rhinitis Treatment
July 16, 2013
- Manipulation of Data Cannot Be Confirmed Based on Results of University’s Investigation: Novartis Pharma
July 16, 2013
- Nippon Chemiphar Considers Establishing Manufacturing Base in Vietnam
July 16, 2013
- Otsuka Forms Clinical Research Firm in UK as Europe’s R&D Hub
July 12, 2013
- Cancer, CNS Diseases to Be Important Fields for MSD Over Next 10 Years: Pres. Alvarez
July 12, 2013
- Anti-HIV Treatment Prezista Naive Tablet 800 mg Approved: Janssen
July 12, 2013
- Daiichi Sankyo Voluntarily Recalls Mevalotin Granules 1% Due to Contamination with Vitamin Capsule
July 12, 2013
- Empagliflozin Alone Lowers Blood Glucose Level: BI, Eli Lilly
July 11, 2013
- Sanofi Begins Domestic PII Study of Vaccine Against CDIs
July 11, 2013
- Mediceo’s New Tokyo Logistics Center Completed, Operations to Start in September
July 11, 2013
- Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
- Sumitomo Bakelite Files Application for Gene Chip for Cancer Diagnosis
July 11, 2013
- Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…